Magnesium Use in Arrhythmias
Magnesium is specifically indicated for torsades de pointes (polymorphic VT with prolonged QT) where it effectively suppresses and prevents recurrences, but it should NOT be used for polymorphic VT with normal QT or other ventricular tachyarrhythmias. 1
Primary Indication: Torsades de Pointes
For torsades de pointes associated with long QT interval, IV magnesium is the pharmacological treatment of choice after defibrillation 1. The mechanism involves suppressing fluctuations in the myocardial action potential that trigger torsades 1. This indication is supported by small case series showing effectiveness in both terminating and preventing recurrent episodes 1.
Key Clinical Context for Torsades:
- Risk increases when corrected QT interval exceeds 500 milliseconds, especially with bradycardia 1
- Can be inherited (genetic) or acquired (drugs, electrolyte imbalances) 1
- Defibrillation terminates the rhythm but doesn't prevent recurrence—magnesium does 1
Critical Adjunctive Measures:
- Always correct hypokalemia alongside magnesium administration 1
- Avoid antiarrhythmic medications that prolong QT (they worsen torsades) 1
- Avoid β-blockers acutely (can precipitate torsades by worsening bradycardia) 1
- For bradycardia-precipitated torsades, seek expert consultation for overdrive pacing or isoproterenol 1
Where Magnesium Does NOT Work
In the absence of long QT, magnesium has NOT been shown effective for polymorphic VT or other ventricular tachyarrhythmias 1. A case series of 5 patients demonstrated no benefit for polymorphic VT with normal QT 1. For these cases, treat the underlying cause (myocardial ischemia with β-blockers/emergent intervention, plus lidocaine and amiodarone with defibrillation) 1.
Dosing and Administration
For Torsades/Eclampsia (FDA-approved):
- Initial IV dose: 4-5 g diluted in 250 mL D5W or normal saline, infused over several minutes 2
- Alternative: 1-2 g/hour by constant IV infusion after initial bolus 2
- Therapeutic serum level: 2.5-7.5 mEq/L for anticonvulsant effect 2
For Paroxysmal Atrial Tachycardia:
- 3-4 g IV over 30 seconds (only if simpler measures failed and no myocardial damage) 2
Pharmacokinetics and Safety
- Onset: Immediate with IV administration, lasting ~30 minutes 2
- Excretion: Solely renal—adjust in renal insufficiency 2
- Maximum dose: 30-40 g/24 hours in normal renal function; 20 g/48 hours in severe renal insufficiency 2
Monitoring Requirements:
- Deep tendon reflexes (disappear at ~10 mEq/L) 2
- Respiratory function (paralysis risk at 10 mEq/L) 2
- Heart block risk at 10 mEq/L or lower 2
- Serum levels >12 mEq/L may be fatal 2
Additional Arrhythmia Applications (Lower Evidence)
While the 2025 AHA guidelines focus on torsades, research suggests potential benefit in:
- Atrial fibrillation with rapid ventricular response: Meta-analysis shows improved rate and rhythm control when added to standard therapy 3
- Post-cardiac surgery arrhythmias: Reduced incidence of both atrial and ventricular arrhythmias 4
- Digitalis toxicity: Useful for both supraventricular and ventricular arrhythmias 5
- Multifocal atrial tachycardia 5
However, these applications lack the strong guideline support that torsades has and should be considered adjunctive therapy.
Critical Pitfalls to Avoid
- Do not use magnesium for monomorphic VT or shock-resistant VF—it is ineffective 5
- Do not use for polymorphic VT with normal QT—treat underlying ischemia instead 1
- Always check renal function before dosing—magnesium is renally excreted 2
- Monitor for toxicity with serial neurological and cardiovascular assessments 2
- Correct potassium deficiency simultaneously—hypokalemia often coexists and must be addressed 1